The association between longitudinal changes in serum glucose level and longitudinal changes in [18F] Fluorodeoxyglucose-PET (FDG PET) measurements of Alzheimer’s disease (AD) risk are unknown.
Objective:
To investigate whether variation in serum glucose levels across time are associated with changes in FDG PET measurements of cerebral metabolic rate for glucose (rCMRgl) in brain regions preferentially affected by Alzheimer’s disease (AD).
Methods:
Participants are a subset of a prospective cohort study investigating FDG PET, apolipoprotein E (APOE) ɛ4, and risk for AD which includes data from baseline, interim, and follow up visits over 4.4±1.0-years. An automated brain-mapping algorithm was utilized to characterize and compare associations between longitudinal changes in serum glucose levels and longitudinal changes in rCMRgl.
Results:
This study included 80 adults aged 61.5±5 years, including 38 carriers and 42 non-carriers of the APOE ɛ4 allele. Longitudinal increases in serum glucose levels were associated with longitudinal CMRgl decline in the vicinity of parietotemporal, precuneus/posterior cingulate, and prefrontal brain regions preferentially affected by AD (p < 0.05, corrected for multiple comparisons). Findings remained significant when controlled for APOE ɛ4 status and baseline and advancing age.
Conclusions:
Additional studies are needed to clarify and confirm the relationship between longitudinal changes in peripheral glucose and FDG PET measurements of AD risk. Future findings will set the stage on the use of FDG PET in the evaluation of possible interventions that target risk factors for the development of AD.
ReimanEM, ChenK, AlexanderGE, CaselliRJ, BandyD, OsborneD, SaundersAM, HardyJ (2005) Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc Natl Acad Sci U S A102, 8299–8302.
2.
GottesmanII, GouldTD (2003) The endophenotype concept in psychiatry: Etymology and strategic intentions. Am J Psychiatry160, 636–645.
3.
AlexanderGE, ChenK, PietriniP, RapoportSI, ReimanEM (2002) Longitudinal PET evaluation of cerebral metabolic decline in dementia: A potential outcome measure in Alzheimer’s disease treatment studies. Am J Psychiatry159, 738–745.
4.
ReimanEM, CaselliRJ, YunLS, ChenK, BandyD, MinoshimaS (1996) Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med334, 752–758.
5.
KnopmanDS, JackCR, WisteHJ, LundtES, WeigandSD, VemuriP, LoweVJ, KantarciK, GunterJL, SenjemML, MielkeMM, RobertsRO, BoeveBF, PetersenRC (2014) 18F-fluorodeoxyglucose positron emission tomography, aging, and apolipoprotein E genotype in cognitively normal persons. Neurobiol Aging35, 2096–2106.
6.
BakerLD, CrossDJ, MinoshimaS, BelongiaD, WatsonGS, CraftS (2011) Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol68, 51–57.
7.
BurnsCM, ChenK, KaszniakAW, LeeW, AlexanderGE, BandyD, FleisherAS, CaselliRJ, ReimanEM (2013) Higher serum glucose levels are associated with cerebral hypometabolism in Alzheimer regions. Neurology80, 1557–1564.
8.
RobertsRO, KnopmanDS, ChaRH, MielkeMM, PankratzVS, BoeveBF, KantarciK, GedaYE, JackCR, PetersenRC, LoweVJ (2014) Diabetes and elevated hemoglobin A1c levels are associated with brain hypometabolism but not amyloid accumulation. J Nucl Med55, 759–764.
9.
WilletteAA, BendlinBB, StarksEJ, BirdsillAC, JohnsonSC, ChristianBT, OkonkwoOC, La RueA, HermannBP, KoscikRL, JonaitisEM, SagerMA, AsthanaS (2015) Association of insulin resistance with cerebral glucose uptake in late middle-aged adults at risk for Alzheimer disease. JAMA Neurol72, 1013–1020.
10.
BondiM, SalmonD, KaszniakAW (2010) The neuropsychology of dementia. In Neuropsychological assessment of neuropsychiatric disorders,
GrantI,
AdamsKM, eds, Oxford University Press, New York.
11.
ReimanEM, CaselliRJ, YunLS, ChenK, BandyD, MinoshimaS, ThibodeauSN, OsborneD (1996) Preclinical evidence of Alzheimer’s disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med334, 752–758.
12.
ReimanEM, CaselliRJ, ChenK, AlexanderGE, BandyD, FrostJ (2001) Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer’s disease. Proc Natl Acad Sci U S A98, 3334–3339.
13.
CaselliRJ, ReimanEM, OsborneD, HentzJG, BaxterLC, HernandezJL, AlexanderGG (2004) Longitudinal changes in cognition and behavior in asymptomatic carriers of the APOE e4 allele. Neurology62, 1990–1995.
14.
HachinskiV, IadecolaC, PetersenRC, BretelerMM, NyenhuisDL, BlackSE, PowersWJ, DeCarliC, MerinoJG, KalariaRN, VintersHV, HoltzmanDM, RosenbergGA, WallinA, DichgansM, MarlerJR, LeblancGG (2006) National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive impairment harmonization standards. Stroke37, 2220–2241.
15.
FolsteinMF, FolsteinSE, McHughPR (1975) Mini-mental state. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res12, 189–198.
16.
HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23, 56–62.
17.
TalairachJ, TournouxP (1998), Co-planar sterotaxic atlas of the human brain, Thieme, New York.
18.
ReimanEM, LaneRD, AhernGL, SchwartzGE, DavidsonRJ, FristonKJ (1997) Neuroanatomical correlates of externally and internally generated human emotion. Am J Psychiatry154, 918–925.
19.
WaxmanAD, HerholzK, LewisD, HerscovitchP, MinoshimaS, MasanorI, DevousMD, MountzJM (2009) Society of Nuclear Medicine procedure guideline for FDG PET brain imaging version 1[online]. Available at: http://interactive.snm.org/index.cfm? PageID=8490. Accessed November 6, 2017.
20.
ReyA (1958) L’examen clinique en psychologie, Presses universitaire de France, Paris.
21.
ReyA, GaillardF (1968) Association des amis d’Andre R, Epreuves visuo-spatiales, Delachaux & Niestle, Neuchatel Suisse.
22.
BentonAL, HamsherKd, SivanAB (1994) Multilingual Aphasia Examination: Manual of Instruction, AJA Associates, Iowa City.
23.
HamiltonM (1960) A rating scale for depression. J Neurol Neurosurg Psychiatry23, 56–62.
24.
WatsonGS, CraftS (2004) Modulation of memory by insulin and glucose: Neuropsychological observations in Alzheimer’s disease. Eur J Pharmacol490, 97–113.
25.
BackeströmA, ErikssonS, NilssonLG, OlssonT, RolandssonO (2015) Glucose but not insulin or insulin resistance is associated with memory performance in middle-aged non-diabetic women: A cross sectional study. Diabetol Metab Syndr7, 20.
26.
DahleCL, JacobsBS, RazN (2009) Aging, vascular risk, and cognition: Blood glucose, pulse pressure, and cognitive performance in healthy adults. Psychol Aging24, 154–162.
27.
S Roriz-FilhoJ, Sa-RorizTM, RossetI, CamozzatoAL, SantosAC, ChavesML, MorigutiJC, Roriz-CruzM (2009) (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta1792, 432–443.
28.
MoranC, PhanTG, ChenJ, BlizzardL, BeareR, VennA, MunchG, WoodAG, ForbesJ, GreenawayTM, PearsonS, SrikanthV (2013) Brain atrophy in type 2 diabetes: Regional distribution and influence on cognition. Diabetes Care36, 4036–4042.
29.
TournoyJ, LeeDM, PendletonN, O’NeillTW, O’ConnorDB, BartfaiG, CasanuevaFF, FinnJD, FortiG, GiwercmanA, HanTS, HuhtaniemiIT, KulaK, LeanME, MoseleyCM, PunabM, SilmanAJ, VanderschuerenD, WuFC, BoonenS, EMAS study group (2010) Association of cognitive performance with the metabolic syndrome and with glycaemia in middle-aged and older European men: The European Male Ageing Study. Diabetes Metab Res Rev26, 668–676.
30.
PaniLN, KorendaL, MeigsJB, DriverC, ChamanyS, FoxCS, SullivanL, D’AgostinoRB, NathanDM (2008) Effect of aging on A1C levels in individuals without diabetes: Evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004. Diabetes Care31, 1991–1996.
31.
DubowitzN, XueW, LongQ, OwnbyJG, OlsonDE, BarbD, RheeMK, MohanAV, Watson-WilliamsPI, JacksonSL, TomoloAM, JohnsonTM, PhillipsLS (2014) Aging is associated with increased HbA1c levels, independently of glucose levels and insulin resistance, and also with decreased HbA1c diagnostic specificity. Diabet Med31, 927–935.
32.
CranePK, WalkerR, HubbardRA, LiG, NathanDM, ZhengH, HaneuseS, CraftS, MontineTJ, KahnSE, McCormickW, McCurrySM, BowenJD, LarsonEB (2013) Glucose levels and risk of dementia. N Engl J Med369, 540–548.
33.
MatthewsDR, HoskerJP, RudenskiAS, NaylorBA, TreacherDF, TurnerRC (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia28, 412–419.
34.
ThambisettyM, Beason-HeldLL, AnY, KrautM, MetterJ, EganJ, FerrucciL, O’BrienR, ResnickSM (2013) Impaired glucose tolerance in midlife and longitudinal changes in brain function during aging. Neurobiol Aging34, 2271–2276.
35.
KawasakiK, IshiiK, SaitoY, OdaK, KimuraY, IshiwataK (2008) Influence of mild hyperglycemia on cerebral FDG distribution patterns calculated by statistical parametric mapping. Ann Nucl Med22, 191–200.
36.
IshibashiK, KawasakiK, IshiwataK, IshiiK (2015) Reduced uptake of 18F-FDG and 15O-H2O in Alzheimer’s disease-related regions after glucose loading. J Cereb Blood Flow Metab35, 1380–1385.
WilletteAA, JohnsonSC, BirdsillAC, SagerMA, ChristianB, BakerLD, CraftS, OhJ, StatzE, HermannBP, JonaitisEM, KoscikRL, La RueA, AsthanaS, BendlinBB (2015) Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement11, 504–510.e501.
39.
CaselliRJ, ReimanEM (2013) Characterizing the preclinical stages of Alzheimer’s disease and the prospect of presymptomatic intervention. J Alzheimers Dis33(Suppl 1), S405–S416.
40.
ReimanEM, LangbaumJB, FleisherAS, CaselliRJ, ChenK, AyutyanontN, QuirozYT, KosikKS, LoperaF, TariotPN (2011) Alzheimer’s Prevention Initiative: A plan to accelerate the evaluation of presymptomatic treatments. J Alzheimers Dis26(Suppl 3), 321–329.
